Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.2 - $0.5 $2,004 - $5,010
-10,020 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$0.41 - $0.63 $328 - $504
-800 Reduced 7.39%
10,020 $6,000
Q4 2021

Feb 08, 2022

SELL
$0.57 - $1.29 $113 - $258
-200 Reduced 1.81%
10,820 $6,000
Q3 2021

Nov 02, 2021

SELL
$1.11 - $1.7 $1,110 - $1,700
-1,000 Reduced 8.32%
11,020 $14,000
Q2 2021

Aug 11, 2021

BUY
$1.46 - $2.25 $1,197 - $1,845
820 Added 7.32%
12,020 $20,000
Q1 2021

May 14, 2021

BUY
$1.77 - $2.93 $1,327 - $2,197
750 Added 7.18%
11,200 $20,000
Q4 2020

Feb 12, 2021

SELL
$2.13 - $3.26 $16,294 - $24,939
-7,650 Reduced 42.27%
10,450 $22,000
Q3 2020

Nov 04, 2020

BUY
$1.53 - $3.13 $2,907 - $5,947
1,900 Added 11.73%
18,100 $54,000
Q2 2020

Jul 17, 2020

SELL
$0.48 - $1.75 $480 - $1,750
-1,000 Reduced 5.81%
16,200 $24,000
Q1 2020

Apr 21, 2020

BUY
$0.56 - $0.97 $140 - $242
250 Added 1.47%
17,200 $10,000
Q3 2019

Nov 07, 2019

BUY
$0.81 - $1.06 $13,729 - $17,967
16,950 New
16,950 $16,000
Q4 2018

Feb 11, 2019

SELL
$0.39 - $3.47 $12,870 - $114,510
-33,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$1.39 - $2.25 $45,870 - $74,250
33,000 New
33,000 $70,000

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.